Monoclonal antibodies that block immunological checkpoints to prevent T cell exhaustion and improve tumor destruction by cytotoxic CD8 + T cells are effective in mCRC patients with dMMR-MSI-H. The gene discussed is CD8A; the disease is neoplasm.